As peptide therapeutics continue to gain interest from the medical community and pharmaceutical companies, concerns regarding the cost of manufacturing also grow. Cost includes the expense of reagents and solvents, including DMF and NMP, used in the synthesis but also subsequent disposal.
With growing motivations to improve the "green" characteristics of chemistry (reducing waste, reducing use of harmful solvents, etc), today's post will highlight some recent work evaluating alternative solvents for use in solid phase peptide synthesis.